The domestic market of antiasthmatic inhalers has broken the 10 billion mark, and top 5 varieties account for more than 85%!

May 1 this year is the 20th World Asthma Day The World Health Organization launched this commemorative activity to strengthen the understanding of the current situation of asthma, attach importance to the prevention and treatment of airway diseases, and enhance the prevention and management of respiratory diseases for all mankind Inhalant is a kind of drug aerosol formed by dispersing the drug into mist by depending on the projective agent, compressed air or special device It has the characteristics of targeted drug delivery Compared with oral and injection drugs, inhalant has the advantages of small stimulation, convenient use and good compliance of patients Inhalant can avoid the first pass effect of liver and small toxic and side effects It is suitable for the long-term treatment of the elderly and children The world Who has recommended it as the first choice therapy for respiratory diseases such as asthma and COPD, which has a broad market prospect According to the CMH monitoring data of Zhongkang, the scale of domestic respiratory system medication in 2017 reached 143154 million yuan, an increase of 4.23% over the previous year Among them, the market scale of antiasthmatic drugs reached 24.131 billion yuan, an increase of 4.86% over the previous year It is worth noting that antiasthmatic inhalers are one of the important varieties in the treatment market In 2017, the number of antiasthmatic inhalers in China exceeded 10 billion, reaching 10.605 billion yuan, accounting for 7.41% of the total market of respiratory system drugs Data source of market scale of antiasthmatic inhalers in 2013-2017 (100 million yuan): at present, the main clinical inhalers of Zhongkang CMH are glucocorticoid budesonide, fluticasone, beclomethasone, etc.; β - adrenergic receptor agonists are formoterol, salbutamol, terbutaline, etc.; the main varieties of anticholinergic substances are ipratropium bromide, tiotropium bromide, etc Corticosteroids account for half of the total anti asthma inhaled preparations, including corticosteroids, β - adrenergic receptor agonists, M-cholinergic receptor antagonists and compound preparations Among them, the proportion of corticosteroids in inhaled preparations increased year by year, reaching 57.0% in 2017, accounting for half of the country; the second is compound β receptor agonists / corticosteroids accounting for 26.8% Antiasthmatic inhalers are recommended in the guidelines for the prevention and treatment of bronchial asthma and the guidelines for the diagnosis and treatment of bronchial asthma in children However, due to the high price of inhaled preparations compared with oral antiasthmatic drugs, the market is dominated by foreign drugs The domestic public medical institutions terminal market, urban level hospitals and county level hospitals are the main sales channels, while community health centers and rural grass-roots medical care are basically less With the improvement of drug use level, antiasthmatic inhalers have been higher than the rapid growth of traditional drugs According to the CMH monitoring data of Zhongkang, the total market size of the top 5 varieties of anti asthma inhalers in 2017 reached 9.2 billion yuan, an increase of 15.26% over the previous year, accounting for more than 85% of the total market of anti asthma inhalers The top 5 drugs are budesonide, salmeterol, flumotol, tiotropium bromide and salbutamol Data source: budesonide, the leading market of Zhongkang CMH 2 budesonide, belongs to glucocorticoid inhaler, which is developed and listed by AstraZeneca (trade name: pumik) for the treatment of asthma, chronic obstructive pulmonary disease (COPD) and non infectious rhinitis There are two dosage forms: dry powder inhaler and inhalation suspension used through atomizer According to the latest financial report data released by AstraZeneca, the global sales market of budesonide in 2017 was US $1.176 billion, an increase of 10.84% compared with the previous year After entering the new century, driven by the sales strategy, the cumulative sales reached US $18 billion, showing remarkable performance However, with the expiration of the patent of budesonide inhalation suspension and the listing of generic drugs in 2018, the market share of original research drugs may be squeezed At present, budesonide drugs listed in China include AstraZeneca, Italy's chiesi fariceutici, Finland's Orion Corporation, lunambert, Shanghai Xinyi and Taiwan's Jianqiao Xinyuan According to CMH monitoring data of Zhongkang, the market share of domestic budesonide reached 46.9% in 2017, an increase of 18.04% over the previous year 3 Salmeterol and fluffy growth salmeterol and ticasone is one of GlaxoSmithKline's top products Its trade name is Seretide, which is used to treat asthma and COPD According to GSK financial report data, in 2017, the global sales of sametrototicasson reached USD 5.697 billion, an increase of 6.19% over the previous year In the field of antiasthmatic inhalers in China, salmeterol and ticasone are high priced drugs Influenced by GlaxoSmithKline's experience of "commercial bribery" in China and the fierce competition from budesonide, Seretide has been declining year by year since 2013 Its market share has declined from 28.40% in 2013 to 18.66% in 2017, but its growth rate has increased by 15.20% year on year, ranking second in the sales of anti asthma inhalers, It is expected that the market of sametrototicasson will gradually regain its lost ground in 2018 Budesonide formoterol has been increasing year by year Budesonide formoterol is an anti asthma compound inhaler developed and listed by AstraZeneca company It is composed of two components, a fast release long-acting β 2-agonist and an anti-inflammatory corticosteroid It was approved and listed by the US FDA in 2006, and its trade name is Symbicort In 2014, the global market of budesonide fomotro reached a peak of US $3.801 billion, and the market performance is still active In 2017, the global market size of SINOSURE was US $2.803 billion, down 6.22% year on year According to CMH data, the market share of domestic budesonide formoterol powder inhalers in 2017 was about 8%, down 1% year on year, and was exclusively operated by AstraZeneca In recent years, in the field of new drug research and development, the progress of small molecule new drugs against asthma has been slow With the extension of new drug research and development pipeline in the world, large molecule biological antibody drugs have entered the market of anti asthma and COPD In 2017, Novartis' overall market of omazumab increased by 16.38% year on year, reaching US $2.742 billion, becoming a pioneer in the field of anti asthma and anti allergy On August 24, 2017, omazumab injection was approved to be marketed in China (trade name: Zhuolu) for the treatment of adults and adolescents (12 years and above) with moderate to severe persistent allergic asthma who still can not effectively control symptoms after ICS / Laba treatment In addition to omazumab injection, In the past three years, FDA approved drugs in the field of asthma also include: mepolizumab (nucala) of GlaxoSmithKline, reslizumab (cinqair) of Teva company, and dipilumab (dupixent) of Sanofi / regenerator, and benralizumab (fasenra) of MedImmune, a subsidiary of AstraZeneca 。